Effect of HMG on Pregnancy Outcomes in Patients undergoing IUI Cycle -An Analysis of 1230 IUI Cycles

Abstract Background: This aim of this study was to evaluate the effect of human menopause gonadotropin (HMG) on pregnancy outcomes of infertility patients with intrauterine insemination (IUI) treatments. Methods: This retrospective cohort study analyzed couples using 75 IU HMG as initiate ovarian stimulation method for IUI from January 2015 to December 2019. Couples were divided into four groups according to a total dose of HMG: 189 cycles with a dose <500 IU, 601 with a dose 500 to1000 IU, 199 with a dose 1000 to 1500 IU and 241 with a dose ＞1500 IU. The differences in baseline characteristics and pregnancy outcomes including among the four groups were investigated. We used a logistic regression model to further study the association between various doses of HMG and pregnancy outcomes and adjusted for confounding factors. Results: The study included 792 couples with 1230 cycles, and pregnancy was achieved in 212 (17.2%) cycles, while live birth was achieved in 176 (14.3%) cycles. Stratified analyses revealed that a higher dose of HMG was associated with increased pregnancy rate (PR), live birth rate (LBR), endometrial thickness (EMT) on insemination day, number of follicle ≥18 mm, serum estrogen 2( E2) level, and EMT on the trigger day among four groups, which were all statistically different (P＜0.05). The logistic regression indicated that both PR and LBR were positively associated with the total dose and day of HMG, which were statistically different (P＜0.05). Conclusion: Increasing the total dose and day of HMG may benefit the serum E2 level, EMT, follicle development, and pregnancy outcomes in 75IU HMG stimulated IUI cycles.